RNAZ

14.92

0.47% 0.07

Dopo l'orario di chiusura: 14.63 -0.29 -1.94%

Transcode Therapeutics Inc (RNAZ)

Panoramica Notizia Cronologia dei prezzi Financials Perché RNAZ Giù? Forum Previsione Frazionamento azionario

Precedente Chiudi:

$14.85

Aprire:

$14.76

Volume 24 ore:

54,079

Relative Volume:

0.36

Capitalizzazione di mercato:

$12.44M

Reddito:

Utile/perdita netta:

$-14.93M

Rapporto P/E:

-0.0561

EPS:

-266.137

Flusso di cassa netto:

$-15.87M

1 W Prestazione:

+0.95%

1M Prestazione:

+27.85%

6M Prestazione:

+49.43%

1 anno Prestazione:

-97.62%

Intervallo 1D:

$14.57

$15.49

Intervallo di 1 settimana:

$13.29

$15.94

Portata 52W:

$6.1478

$711.48

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Nome

Transcode Therapeutics Inc

Settore

Healthcare (1140)

Industria

Biotechnology (637)

Telefono

857-301-6857

Indirizzo

6 LIBERTY SQUARE, BOSTON

Dipendente

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

RNAZ's Discussions on Twitter

Confronta RNAZ con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RNAZ Transcode Therapeutics Inc	14.92	13.09M	0	-14.93M	-15.87M	-266.14
VRTX Vertex Pharmaceuticals Inc	408.61	105.69B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	481.07	61.52B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	569.17	60.69B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	837.28	50.05B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	318.02	35.25B	4.56B	-176.77M	225.30M	-1.7177

Transcode Therapeutics Inc Borsa (RNAZ) Ultime notizie

Oct 15, 2025

Can TransCode Therapeutics Inc. stock weather global recessionRecession Risk & Real-Time Market Trend Scan - newser.com

Oct 15, 2025

Why TransCode Therapeutics Inc. stock is considered a top pick2025 Analyst Calls & Trade Opportunity Analysis Reports - newser.com

Oct 15, 2025

Does TransCode Therapeutics Inc. qualify in momentum factor screening2025 Pullback Review & Expert Approved Momentum Ideas - newser.com

Oct 15, 2025

Heatmap analysis for TransCode Therapeutics Inc. and competitorsJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com

Oct 15, 2025

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - MSN

Oct 15, 2025

Top chart patterns to watch in TransCode Therapeutics Inc.2025 Big Picture & Scalable Portfolio Growth Ideas - newser.com

Oct 15, 2025

How to manage a losing position in TransCode Therapeutics Inc.2025 Bull vs Bear & Real-Time Volume Analysis - newser.com

Oct 15, 2025

TransCode reports positive safety data from TTX-MC138 phase 1a trial - Investing.com India

Oct 15, 2025

Is TransCode Therapeutics Inc. stock oversold or undervaluedPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com

Oct 15, 2025

Is TransCode Therapeutics Inc. stock poised for growthMarket Volume Report & High Win Rate Trade Alerts - newser.com

Oct 15, 2025

Oct 14, 2025

TransCode Therapeutics Advances Cancer Treatment After Successful Phase 1a Trial of TTX-MC138 - citybuzz -

Oct 14, 2025

TransCode reports positive safety data from TTX-MC138 phase 1a trial By Investing.com - Investing.com South Africa

Oct 14, 2025

Transcode Therapeutics’ TTX-MC138 achieves safety endpoint in Phase 1a study - TipRanks

Oct 14, 2025

Transcode Therapeutics completes phase 1a trial with TTX-MC138 in metastatic disease at ESMOSEC filing - MarketScreener

Oct 14, 2025

TransCode Therapeutics, Inc. Completes Phase 1a Clinical Trial with TTX-MC138 - TradingView

Oct 14, 2025

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO - WV News

Oct 14, 2025

Is TransCode Therapeutics Inc. trending in predictive chart modelsJuly 2025 Decliners & Community Consensus Picks - newser.com

Oct 14, 2025

Oct 13, 2025

Exit strategy if you’re trapped in TransCode Therapeutics Inc.July 2025 Gainers & Real-Time Buy Zone Alerts - newser.com

Oct 13, 2025

Is a relief rally coming for TransCode Therapeutics Inc. holdersJuly 2025 Reactions & Daily Profit Focused Screening - newser.com

Oct 13, 2025

Using Bollinger Bands to evaluate TransCode Therapeutics Inc.2025 Breakouts & Breakdowns & Risk Managed Investment Entry Signals - newser.com

Oct 13, 2025

CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs - The Star | Malaysia

Oct 13, 2025

Oct 09, 2025

Does TransCode Therapeutics Inc. fit your quant trading modelJuly 2025 WrapUp & Accurate Trade Setup Notifications - newser.com

Oct 09, 2025

CK Life Merges Polynoma with TransCode in $125M DealNews and Statistics - IndexBox

Oct 09, 2025

CK Life Sciences sees low geopolitical risks in a US merger - The Standard (HK)

Oct 09, 2025

Multi asset correlation models including TransCode Therapeutics Inc.July 2025 Highlights & Risk Managed Investment Strategies - newser.com

Oct 09, 2025

TransCode Therapeutics (NASDAQ:RNAZ) Earns “Sell (E+)” Rating from Weiss Ratings - Defense World

Oct 09, 2025

Critical Analysis: Century Therapeutics (NASDAQ:IPSC) and TransCode Therapeutics (NASDAQ:RNAZ) - Defense World

Oct 09, 2025

CKLIFE SCIENCES Estimates Completion of TransCode Preferred Stock Conversion in 6 Mths at Earliest - AASTOCKS.com

Oct 09, 2025

How hedge fund analytics apply to TransCode Therapeutics Inc. stockJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com

Oct 09, 2025

Oct 08, 2025

TransCode Therapeutics Acquires Polynoma, Secures $25 Million Investment to Advance Oncology Pipeline - citybuzz -

Oct 08, 2025